Can circulating tumor and exosomal nucleic acids act as biomarkers for pancreatic ductal adenocarcinoma?

Daniel S K Liu^{1

2}, Mireia Mato Prado², Elisa Giovannetti^{3

4}, Long R Jiao¹, Jonathan Krell², Adam E Frampton^{1

2}

Affiliations

¹ a HPB Surgical Unit, Dept. of Surgery & Cancer , Imperial College, Hammersmith Hospital campus , London , UK.
² b Division of Cancer, Dept. of Surgery & Cancer , Imperial College , London , UK.
³ c Department of Medical Oncology, Cancer Center Amsterdam , Amsterdam UMC, VU University Medical Center (VUmc), 1081 HV , , Amsterdam , The Netherlands.
⁴ d Fondazione Pisana per la Scienza , 56017 , Pisa , Italy.

Editorial

Daniel S K Liu et al. Expert Rev Mol Diagn. 2019 Jul.

. 2019 Jul;19(7):553-558.

doi: 10.1080/14737159.2019.1622414. Epub 2019 Jun 10.

Daniel S K Liu^{1

2}, Mireia Mato Prado², Elisa Giovannetti^{3

4}, Long R Jiao¹, Jonathan Krell², Adam E Frampton^{1

2}

¹ a HPB Surgical Unit, Dept. of Surgery & Cancer , Imperial College, Hammersmith Hospital campus , London , UK.
² b Division of Cancer, Dept. of Surgery & Cancer , Imperial College , London , UK.
³ c Department of Medical Oncology, Cancer Center Amsterdam , Amsterdam UMC, VU University Medical Center (VUmc), 1081 HV , , Amsterdam , The Netherlands.
⁴ d Fondazione Pisana per la Scienza , 56017 , Pisa , Italy.

No abstract available

Keywords: Circulating tumor DNA (ctDNA); KRAS; PDAC; biomarker; exosomes; pancreatic ductal adenocarcinoma; survival.

Publication types